Chemours (NYSE:CC) Stock Gets Price Target Cut from Truist Financial

Key Points

• Truist cut Chemours’ price target from $20 to $18 but maintained its Buy rating; the new target implies about 31% upside from the cited share price.
• Analyst sentiment is mostly cautious: three analysts rate the stock Buy, nine Hold and one Sell, with a consensus target of $17.55.
• Chemours reported quarterly EPS of $0.21, missing the $0.26 estimate and down from $0.40 a year earlier; revenue rose 3% year over year to $1.54 billion, slightly above expectations.

Chemours (NYSE:CC - Get Free Report) had its target price reduced by research analysts at Truist Financial from $20.00 to $18.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the specialty chemicals company's stock. Truist Financial's price target would suggest a potential upside of 31.05% from the company's current price.

Other research analysts have also issued research reports about the company. The Goldman Sachs Group restated a "neutral" rating and set a $16.00 price objective on shares of Chemours in a research report on Friday, October 9th. BMO Capital Markets lowered their price target on Chemours from $26.00 to $18.00 and set an "outperform" rating for the company in a research report on Thursday, August 13th. Weiss Ratings downgraded Chemours from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. lowered their price objective on shares of Chemours from $22.00 to $15.00 and set a "neutral" rating for the company in a research report on Thursday, August 13th. Finally, Royal Bank Of Canada lowered Chemours from an "outperform" rating to a "sector perform" rating and set a $14.00 price target for the company. in a report on Tuesday, October 13th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Chemours has an average rating of "Hold" and a consensus target price of $17.55.

Chemours Price Performance

CC traded up $0.65 on Wednesday, hitting $13.73. 1,215,368 shares of the company's stock traded hands, compared to its average volume of 2,803,360. The company's 50 day simple moving average is $14.12 and its 200-day simple moving average is $18.25. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -13.46 and a beta of 1.47. Chemours has a one year low of $10.44 and a one year high of $28.67. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a positive return on equity of 78.76% and a negative net margin of 2.64%. The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the company earned $0.40 earnings per share. The company's revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, research analysts anticipate that Chemours will post 0.83 EPS for the current year.

Insider Activity at Chemours

In other Chemours news, insider Calderon Gerardo Familiar acquired 1,935 shares of Chemours stock in a transaction that occurred on Wednesday, August 12th. The stock was bought at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares of the company's stock, valued at approximately $909,234.91. This represents a 3.42% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shane Hostetter bought 3,350 shares of the stock in a transaction on Thursday, August 6th. The shares were bought at an average price of $14.94 per share, with a total value of $50,049.00. Following the acquisition, the chief financial officer owned 102,698 shares of the company's stock, valued at $1,534,308.12. This trade represents a 3.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 8,663 shares of company stock valued at $130,601 over the last ninety days. 0.85% of the stock is owned by company insiders.

Hedge Funds Weigh In On Chemours

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in Chemours in the 2nd quarter worth approximately $34,000. Allworth Financial LP purchased a new stake in Chemours during the 2nd quarter worth approximately $51,000. State of Wyoming acquired a new position in Chemours during the 2nd quarter valued at approximately $67,000. Nykredit A S acquired a new position in Chemours during the 2nd quarter valued at approximately $99,000. Finally, Sterling Capital Management LLC increased its stake in Chemours by 839.3% during the 3rd quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company's stock valued at $69,000 after purchasing an additional 4,532 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched FaizEon two-phase cooling fluids for AI and high-performance-computing data centers, targeting lower energy and water use as computing heat loads rise. The product could open a new growth opportunity, though its financial contribution is not yet established. Article: Chemours launches FaizEon cooling solutions
• Positive Sentiment: The company forecast fourth-quarter revenue of $1.7 billion–$1.8 billion, above the cited analyst consensus of $1.4 billion. Full-year revenue guidance of $5.9 billion was in line with consensus. Article: Chemours provides earnings guidance
• Neutral Sentiment: Goldman Sachs maintained a Hold rating with a $16 price target, citing strong Q3 results in some respects but weak volumes and a cautious near-term outlook. Article: Goldman Sachs maintains Hold rating
• Negative Sentiment: Q3 adjusted EPS was $0.21, below the $0.26 analyst estimate and down from $0.40 a year earlier. Revenue of $1.54 billion slightly exceeded estimates and rose 3% year over year, but the earnings miss and reported volume weakness weighed on the results. Article: Chemours reports third-quarter results
• Negative Sentiment: Multiple law firms are publicizing a filed securities class action covering investors who bought shares from February 20 to August 4, 2026. The allegations focus on statements about Opteon refrigerant aftermarket demand and distributor inventory; one notice says roughly $65 million in sales may have shifted from 2026 into 2025. The lead-plaintiff deadline is December 7. These reminders add legal and reputational risk, but are not separate new lawsuits. Article: Class-action reminder and allegations

Chemours Company Profile

The Chemours Company NYSE: CC is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.